New data demonstrates long-term skin clearance in patients with moderate to severe plaque psoriasis treated with Janssen’s Tremfya (guselkumab). The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving Tremfya (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis…
FDA Assessment Confirms Positive Safety And Efficacy Of Xarelto
FDA Mini-Sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) and its association with a lower risk of ischemic stroke vs. warfarin. The Janssen Pharmaceutical Companies of Johnson & Johnson announced findings from the U.S. Food and Drug Administration’s (FDA) Mini-Sentinel assessment, confirming the positive safety and efficacy profile of Xarelto (rivaroxaban) established in the phase III…